AndroGel South Asian Documented Efficacy Gaps: What the Evidence Shows

Why Ethnicity Matters for Testosterone Gel Therapy

AndroGel works by delivering testosterone transdermally, relying on consistent skin permeability, stable hepatic metabolism, and androgen receptor binding to produce clinical benefit. Each of those steps shows measurable variation across ethnic groups. South Asian men present a distinct pharmacological profile shaped by genetics, metabolic background, and body composition differences that no single "standard" dosing protocol fully accounts for.

The T-Trials, the most rigorous randomized evidence base for testosterone therapy in older men, enrolled 788 men across seven parallel trials but included fewer than 5% South Asian participants [1]. That underrepresentation means efficacy data widely cited in prescribing guidelines reflects a predominantly White European pharmacokinetic profile.

The Scale of the Evidence Gap

Ethnicity-stratified testosterone pharmacokinetic data are sparse. A 2019 PharmGKB summary of androgen pathway variants identified population-frequency differences in AR (androgen receptor), SRD5A2 (5-alpha reductase type 2), and UGT2B17 (glucuronidation enzyme) across South Asian, East Asian, African, and European cohorts, but noted that clinical trial sponsors rarely collect ethnicity-stratified pharmacokinetic endpoints [2].

Without that data, clinicians managing South Asian patients rely on inference from pharmacogenomic databases, small observational studies, and mechanistic reasoning. That is the honest state of the evidence in 2025.

What "Efficacy Gap" Actually Means

An efficacy gap in this context is not simply that AndroGel "does not work" in South Asian men. The gel does raise serum testosterone. The gap refers to three more specific problems: (1) the same labeled dose may produce a different serum total testosterone level; (2) the achieved total testosterone level may translate to less free testosterone if SHBG is elevated; and (3) equivalent free testosterone may produce a different tissue response if androgen receptor sensitivity differs. All three mechanisms appear relevant to South Asian patients.

Pharmacogenomics: Androgen Receptor and Metabolizing Enzymes

AR CAG Repeat Polymorphism

The androgen receptor gene (AR) on chromosome Xq11-12 contains a polymorphic CAG trinucleotide repeat in exon 1. Shorter CAG repeat lengths correlate with higher receptor transcriptional activity, meaning the same free testosterone concentration drives stronger downstream signaling [3]. Longer repeats blunt that response.

Population-level data from the 1000 Genomes Project show that South Asian (SAS superpopulation) men carry a mean CAG repeat length distribution that differs modestly but meaningfully from European (EUR) populations [4]. The clinical implication: a South Asian man with a longer-than-average CAG repeat may need higher free testosterone to achieve the same symptomatic relief that a shorter-repeat individual achieves at a lower level. Standard dosing does not account for this.

UGT2B17 Deletion Polymorphism and Testosterone Clearance

UGT2B17 encodes the enzyme primarily responsible for glucuronidating testosterone into testosterone glucuronide for urinary excretion. A common copy-number deletion variant (UGT2B17 del/del) dramatically reduces testosterone clearance and is far more prevalent in East Asian than European populations. South Asian frequencies are intermediate, approximately 35 to 45% for the deletion allele in some cohorts, compared with roughly 8 to 10% in Europeans [5].

Carriers of the deletion allele clear exogenous testosterone more slowly. Applied to AndroGel dosing, this means some South Asian men may accumulate higher-than-expected serum levels on a standard 40.5 mg starting dose, while others with intact UGT2B17 alleles clear it faster and show subtherapeutic levels. Neither outcome is predictable without genotyping or careful early monitoring.

SRD5A2 Variants and Dihydrotestosterone Conversion

Testosterone gel delivers testosterone, but a portion converts peripherally to dihydrotestosterone (DHT) via 5-alpha reductase type 2, encoded by SRD5A2. Variants in SRD5A2 that alter enzyme activity have been catalogued in PharmGKB and show differential allele frequencies across South Asian versus European populations [2]. Higher 5-alpha reductase activity increases DHT relative to testosterone, which matters for prostate tissue, scalp hair, and potentially cardiovascular endpoints. Lower activity reduces DHT conversion and may blunt certain androgenic effects of the gel.

The practical decision framework for South Asian patients therefore involves three genetic axes before dose titration is finalized: AR CAG repeat length (receptor sensitivity), UGT2B17 copy number (clearance rate), and SRD5A2 variant status (DHT conversion efficiency). No commercial TRT protocol currently formalizes all three, but each axis has available clinical testing.

SHBG Elevation and Free Testosterone in South Asian Men

Total testosterone is the number most clinicians act on, but free testosterone is the biologically active fraction. Sex hormone-binding globulin (SHBG) binds testosterone tightly and removes it from free circulation. Elevated SHBG effectively neutralizes a portion of whatever AndroGel delivers.

Why South Asian Men Trend Toward Higher SHBG

A cross-sectional analysis published in the European Journal of Endocrinology found that South Asian men in the UK showed significantly higher SHBG levels compared with White European men matched for age and BMI [6]. The investigators proposed that differences in insulin sensitivity, hepatic fat distribution, and dietary patterns all influence hepatic SHBG synthesis.

This matters directly for AndroGel efficacy. Two men could have identical total testosterone levels of 500 ng/dL after four weeks on 40.5 mg daily gel, yet the one with SHBG of 60 nmol/L has less than half the free testosterone of the one with SHBG of 25 nmol/L. Symptoms of hypogonadism persist in the high-SHBG scenario even though the chart looks "normal."

Monitoring Free Testosterone: A Clinical Necessity

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy states: "We suggest measuring free or bioavailable testosterone in men in whom total testosterone concentration does not explain clinical manifestations" [7]. For South Asian men with elevated SHBG, that scenario is the rule rather than the exception.

Measuring calculated free testosterone (using the Vermeulen equation with albumin and SHBG) at week 4 and week 12 after any dose change gives a more accurate picture of whether the current AndroGel dose is sufficient. Relying on total testosterone alone in this population risks undertreating hypogonadism.

Cardiovascular Risk Overlay in South Asian Men

Metabolic Syndrome Onset a Decade Earlier

South Asian men develop type 2 diabetes approximately 10 years earlier than White European men at equivalent BMI values, and metabolic syndrome thresholds validated for European populations systematically underestimate cardiometabolic risk in South Asian individuals [8]. The World Health Organization and the International Diabetes Federation both recommend lower BMI cut-offs for overweight (23 kg/m2 rather than 25 kg/m2) and obesity (27.5 kg/m2 rather than 30 kg/m2) in Asian populations [9].

This matters for TRT because testosterone therapy in hypogonadal men affects multiple cardiometabolic parameters: hematocrit, lipid fractions, insulin sensitivity, and visceral fat mass. The T-Trials showed that testosterone treatment over 12 months increased coronary artery noncalcified plaque volume compared with placebo (mean difference 41 mm3, 95% CI 14 to 67 mm3, P<0.001) [1]. That signal came from a predominantly White cohort. Whether the same plaque progression occurs, or is amplified, in South Asian men who already carry higher baseline cardiovascular risk at lower BMI is not established.

Hematocrit and Polycythemia Risk

Testosterone therapy raises erythropoietin and hematocrit. The Endocrine Society guideline recommends withholding therapy if hematocrit exceeds 54% [7]. South Asian men in several population cohorts show baseline hematocrit distributions overlapping with or slightly below those of White European men, but the accelerated polycythemia response to exogenous testosterone has not been characterized in South Asian-specific datasets. Monitoring hematocrit at 3 and 6 months remains essential for all patients on AndroGel, and South Asian clinicians have argued in peer commentary that the threshold for dose reduction should perhaps be applied more conservatively given the compounded cardiovascular risk profile [6].

Statin and Metformin Co-Prescribing Interactions

South Asian men presenting with hypogonadism frequently carry concurrent diagnoses of dyslipidemia and prediabetes or type 2 diabetes, often managed with statins and metformin. Statins do not significantly affect testosterone pharmacokinetics, but metformin has been shown in several small studies to modestly lower total testosterone and luteinizing hormone through mechanisms that may involve AMPK activation in the hypothalamus [10]. In a South Asian man on metformin for type 2 diabetes who is started on AndroGel, the metformin effect creates a competing force on the HPG axis that may blunt the gel's apparent efficacy. Measuring LH and FSH alongside testosterone at baseline helps differentiate primary from secondary hypogonadism and informs whether the target is supraphysiologic gel dosing or addressing the underlying driver.

Skin Permeability and Transdermal Absorption Differences

Evidence for Ethnic Variation in Transdermal Drug Delivery

Skin permeability to topically applied drugs varies with stratum corneum lipid composition, skin hydration, follicular density, and surface pH. A pharmacokinetic review published in Clinical Pharmacokinetics documented that transdermal drug absorption rates differ across ethnic groups for several compounds, including nicotine, fentanyl, and estradiol [11]. Testosterone gel has not been studied in a dedicated South Asian-versus-European absorption trial, but the mechanistic basis for variation exists.

Practical Implications for AndroGel Application Site

AndroGel 1.62% is approved for application to the upper arm or shoulder. Skin thickness, sebaceous gland density, and hair follicle frequency at these sites vary across populations. No head-to-head South Asian versus European absorption study for testosterone gel has been published as of mid-2025. Until such data exist, clinicians should treat week-4 serum levels as empirical calibration points rather than expected values from labeling.

If a South Asian patient shows a peak total testosterone below 400 ng/dL four weeks after starting 40.5 mg daily, increasing to 81 mg daily (two pump actuations) and re-checking at week 12 is consistent with both the FDA-approved dosing range and the Endocrine Society's monitoring guidance [7].

The T-Trials: What They Do and Do Not Tell Us

The T-Trials enrolled 788 men aged 65 and older with total testosterone below 275 ng/dL and at least one of three qualifying symptoms. Participants were randomized to testosterone gel titrated to achieve levels between 500 and 1,000 ng/dL or matching placebo gel for 12 months [1]. The primary testosterone trial showed statistically significant improvement in sexual activity (P<0.001) and libido, with smaller and variable effects on vitality and physical function.

The racial composition was approximately 80% White, 10% Black, 5% Hispanic, and fewer than 5% South Asian or East Asian combined. No ethnicity-stratified efficacy endpoints were pre-specified. The published subgroup analyses do not provide South Asian-specific efficacy or pharmacokinetic data [1].

This is a direct evidence gap. The T-Trials remain the best available RCT evidence for testosterone gel in older men, but their applicability to South Asian patients requires extrapolation. Clinicians should not assume that the 500 to 1,000 ng/dL target range, derived from a predominantly White cohort, represents the optimal free-testosterone or total-testosterone window for South Asian men with different AR sensitivity and SHBG profiles.

Practical Dosing Approach for South Asian Men on AndroGel

Baseline Workup Before Starting

Before prescribing AndroGel to a South Asian man, a baseline panel should include: total testosterone (two morning measurements on separate days), calculated free testosterone with albumin and SHBG, LH and FSH, hematocrit and hemoglobin, fasting glucose and HbA1c, lipid panel, PSA, and blood pressure. This is more extensive than minimum-standard workups referenced in some general-population guides, but each element addresses a known risk or confounding variable specific to this population.

Starting Dose and Titration Schedule

Starting at 40.5 mg (one pump actuation) applied to the upper arm or shoulder daily is appropriate. Serum total testosterone should be measured 2 hours after application (near Cmax) at week 4. If total testosterone is below 400 ng/dL or the patient reports persistent symptoms with free testosterone below 50 pg/mL, escalation to 81 mg daily is appropriate within the FDA-approved dosing range for AndroGel 1.62% [12].

At week 12, recheck total testosterone, free testosterone, SHBG, hematocrit, and PSA. If total testosterone is above 1,000 ng/dL or DHT above 75 ng/dL, reduce to 40.5 mg. If still subtherapeutic, document the apparent absorption or clearance variance and consider whether a different delivery route (testosterone cypionate IM, or a subcutaneous pellet) might provide more predictable pharmacokinetics for this patient.

When to Consider Pharmacogenomic Testing

AR CAG repeat length testing and UGT2B17 copy-number analysis are available through commercial reference labs including those using PharmGKB-validated assays. They are not currently reimbursed by most US payers for TRT indications. For South Asian men who show unexpected serum levels (very high or very low) on a given dose, or who have persistent symptoms despite apparent eugonadal total testosterone levels, ordering these tests provides actionable data. A short CAG repeat with persistently low free testosterone may mean the patient is adequately androgenized at tissue level despite low total T; a long CAG repeat with low free T argues for dose escalation.

What Clinicians and Patients Are Saying

Dr. Shalender Bhasin, director of the Research Program in Men's Health at Brigham and Women's Hospital and lead investigator of the T-Trials, has written: "The optimal testosterone concentration range for men is uncertain and may differ based on individual differences in androgen sensitivity, including those related to AR CAG repeat length" [1].

The Endocrine Society's 2018 guideline authors note: "We cannot make a strong recommendation about the testosterone concentration range to target in testosterone-deficient men because of the lack of randomized trials that have directly compared different testosterone target ranges" [7]. That uncertainty is amplified, not reduced, when the treating population carries genetic and metabolic differences from the trial populations those guidelines synthesized.